A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors

[1]  Rachelle S. Singleton,et al.  The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. , 2010, Cancer research.

[2]  W. Wilson,et al.  Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A , 2009, Molecular Cancer Therapeutics.

[3]  Rachelle S. Singleton,et al.  DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity. , 2009, Cancer research.

[4]  Shuang-yin Han,et al.  Hypoxia‐mediated up‐regulation of MGr1‐Ag/37LRP in gastric cancers occurs via hypoxia‐inducible‐factor 1‐dependent mechanism and contributes to drug resistance , 2009, International journal of cancer.

[5]  F. Khanim,et al.  The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis. , 2009, Mutation research.

[6]  J. Brown,et al.  Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104. , 2008, Cancer research.

[7]  R. Fisher,et al.  Phase III study of tirapazamine, cisplatin and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck , 2008 .

[8]  G. Scambia,et al.  Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region. , 2008, Gene.

[9]  W. Wilson,et al.  Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine. , 2007, International journal of radiation oncology, biology, physics.

[10]  W. Wilson,et al.  Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia. , 2007, Biochemical pharmacology.

[11]  W. Wilson,et al.  Analysis of the hypoxia-activated dinitrobenzamide mustard phosphate pre-prodrug PR-104 and its alcohol metabolite PR-104A in plasma and tissues by liquid chromatography-mass spectrometry. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[12]  Trevor M Penning,et al.  Human aldo-keto reductases: Function, gene regulation, and single nucleotide polymorphisms. , 2007, Archives of biochemistry and biophysics.

[13]  K. Williams,et al.  Bioreductive drugs: from concept to clinic. , 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).

[14]  Rachelle S. Singleton,et al.  Mechanism of Action and Preclinical Antitumor Activity of the Novel Hypoxia-Activated DNA Cross-Linking Agent PR-104 , 2007, Clinical Cancer Research.

[15]  W. Wilson,et al.  Bystander Effects of Bioreductive Drugs: Potential for Exploiting Pathological Tumor Hypoxia with Dinitrobenzamide Mustards , 2007, Radiation research.

[16]  H. Grossman,et al.  Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response , 2007 .

[17]  K. Parmar,et al.  Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia , 2007, Proceedings of the National Academy of Sciences.

[18]  Timothy W Secomb,et al.  Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. , 2006, Journal of the National Cancer Institute.

[19]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[20]  A. Jaiswal,et al.  NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs. , 2006, Biochemical pharmacology.

[21]  R. Fisher,et al.  Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Takashi Suzuki,et al.  17β-Hydroxysteroid dehydrogenases in human endometrium and its disorders , 2006, Molecular and Cellular Endocrinology.

[23]  A. Harris,et al.  Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Crowley,et al.  Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  K. Oishi,et al.  Localization of cyclooxygenases-1 and -2, and prostaglandin F synthase in human kidney and renal cell carcinoma. , 2005, Biochemical and biophysical research communications.

[26]  D. Kerr,et al.  NITROREDUCTASE: A PRODRUG‐ACTIVATING ENZYME FOR CANCER GENE THERAPY , 2004, Clinical and experimental pharmacology & physiology.

[27]  A. Minchinton,et al.  Microregional Effects of Gemcitabine in HCT-116 Xenografts , 2004, Cancer Research.

[28]  W. Wilson,et al.  Oxygen Dependence of the Metabolic Activation and Cytotoxicity of Tirapazamine: Implications for Extravascular Transport andActivity in Tumors , 2004, Radiation research.

[29]  J. Brown,et al.  Exploiting tumour hypoxia in cancer treatment , 2004, Nature Reviews Cancer.

[30]  John Ellis,et al.  Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Chow,et al.  Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. , 2003, Cancer research.

[32]  W. Denny,et al.  Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation. , 2003, Chemical research in toxicology.

[33]  M. Gassmann,et al.  Regulation of the multidrug resistance transporter P‐glycoprotein in multicellular tumor spheroids by hypoxia‐inducible factor‐1 and reactive oxygen species , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  Michael C. Montalto,et al.  Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. , 2002, Cancer research.

[35]  Ian F Tannock,et al.  Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  D. Hedley,et al.  Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  D. Kerr,et al.  Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  O. S. Nielsen,et al.  Hypoxia in human soft tissue sarcomas: Adverse impact on survival and no association with p53 mutations , 2001, British Journal of Cancer.

[39]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[40]  P. Workman,et al.  Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo. , 2000, Molecular pharmacology.

[41]  F. Shepherd,et al.  Comparison of Tirazone (Tirapazamine) and cisplatin vs. etoposide and cisplatin in advanced non-small cell lung cancer (NSCLC): Final results of the international Phase III CATAPULT II Trial , 2000 .

[42]  D. Dunlop,et al.  Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  W. Wilson,et al.  Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. , 2000, Toxicology and applied pharmacology.

[44]  A. Giaccia,et al.  The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. , 1998, Cancer research.

[45]  M. Dewhirst,et al.  Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. , 1996, Cancer research.

[46]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[47]  P. Workman,et al.  Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines. , 1994, International journal of radiation oncology, biology, physics.

[48]  C. Koch.  Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. , 1993, Cancer research.

[49]  F. Friedlos,et al.  Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species. , 1991, Biochemical pharmacology.

[50]  I. Tannock.  The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour. , 1968, British journal of cancer.

[51]  I. Churchill-Davidson.  Oxygenation in radiotherapy. , 1959, The Journal of obstetrics and gynaecology of the British Empire.

[52]  L. H. Gray.  Oxygenation in radiotherapy. I. Radiobiological considerations. , 1957, The British journal of radiology.

[53]  L. H. Gray,et al.  The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy , 1955, British Journal of Cancer.

[54]  若生 康一.  Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer , 2008 .

[55]  W. Denny,et al.  Synthesis of 3H‐ and 2H4‐labelled versions of the hypoxia‐activated pre‐prodrug 2‐[(2‐bromoethyl)‐2,4‐dinitro‐6‐ [[[2‐(phosphonooxy)ethyl]amino]carbonyl]anilino]ethyl methanesulfonate (PR‐104) , 2007 .

[56]  Takashi Suzuki,et al.  17Beta-hydroxysteroid dehydrogenases in human endometrium and its disorders. , 2006, Molecular and cellular endocrinology.

[57]  L. Wilson,et al.  Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial. , 2005, International journal of radiation oncology, biology, physics.

[58]  Richard P. Hill,et al.  The hypoxic tumour microenvironment and metastatic progression , 2004, Clinical & Experimental Metastasis.

[59]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[60]  P Lambin,et al.  Hypoxia as a target for combined modality treatments. , 2002, European journal of cancer.

[61]  B. Teicher,et al.  Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. , 1981, Cancer research.